Filing Analysis
DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings and business updates.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Announcement date: August 10, 2026
- The company released condensed consolidated financial results via a press release (Exhibit 99.1).
DiaMedica Therapeutics provided an update on its DM199 preeclampsia program following a pre-IND meeting with the FDA. The company announced that the FDA has requested an additional non-clinical rabbit study, with results expected in Q2 2026.
🚩 Red Flags
- Regulatory delay: The requirement for an additional non-clinical study may extend the timeline for clinical development of DM199.
📋 Key Facts
- Completed an in-person pre-IND meeting with the FDA regarding DM199 for preeclampsia.
- FDA requested one additional 10-day modified embryo-fetal development (EFD) and pre/postnatal development (PPND) study in a rabbit model.
- Preparations for the required rabbit study have commenced.
- Results from the new non-clinical study are expected by the second quarter of 2026.
DiaMedica Therapeutics Inc. filed an 8-K to announce its condensed consolidated financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the company's third-quarter business update and financial performance.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 12, 2025
- Content includes a press release providing a business update and third quarter 2025 financial results (Exhibit 99.1)
- The information in Item 2.02 is furnished, not filed, under Section 18 of the Exchange Act.
DiaMedica Therapeutics Inc. entered into an At-The-Market (ATM) sales agreement with TD Securities (USA) LLC to facilitate the potential sale of up to $100 million in common shares.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of up to $100 million in new common shares.
- ATM offerings are often used by micro-cap biotech companies to extend cash runway, signaling a need for immediate liquidity.
📋 Key Facts
- Entered into a Sales Agreement with TD Cowen on August 12, 2025.
- Aggregate offering amount: up to $100.0 million in Common Shares.
- The sale will be conducted as an 'at the market' (ATM) offering under Rule 415(a)(4).
- TD Cowen is entitled to compensation of up to 3.0% of gross proceeds.
- Issuance is contingent upon the effectiveness of a new Form S-3 shelf registration statement filed on August 12, 2025.
DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings and business updates.
📋 Key Facts
- Reported date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The company released condensed consolidated financial results via Exhibit 99.1
- Included a business update alongside the financial results
DiaMedica Therapeutics announced the resignation of Chief Medical Officer Lorianne Masuoka, M.D., effective August 4, 2025, and the subsequent appointment of Julie Krop, M.D., to succeed her.
🚩 Red Flags
- Sudden departure of a key executive (CMO) in the biotech sector can sometimes signal internal friction or clinical development setbacks, though 'personal reasons' is cited here.
- Separation agreement includes extended health benefits through October 2026.
📋 Key Facts
- Lorianne Masuoka, M.D. resigned as CMO effective August 4, 2025, for personal reasons.
- The Company entered into a separation agreement with Dr. Masuoka providing health benefits through October 2026.
- Julie Krop, M.D. has been appointed as the new CMO, effective August 11, 2025.
- Dr. Krop brings extensive experience from PureTech Health, Freeline Therapeutics, and AMAG Pharmaceuticals.
DiaMedica Therapeutics Inc. entered into a securities purchase agreement for a private placement of 8,606,426 common shares at $3.50 per share. The company expects to receive approximately $30.1 million in gross proceeds to fund its DM199 preeclampsia clinical development program and general working capital.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of over 8.6 million new shares.
- Liquidated damages clause in the Registration Rights Agreement if filing deadlines are missed.
- Requirement for the company to indemnify selling holders under the registration statement.
📋 Key Facts
- Private placement of 8,606,426 common shares at $3.50 per share.
- Expected gross proceeds: $30.1 million (before fees/expenses).
- Closing expected on or about July 23, 2025.
- Purchasers are existing accredited investors.
- The company must file a Resale Registration Statement within 10 business days of closing.
- Registration statement must be declared effective within 30-75 days to avoid liquidated damages.
DiaMedica Therapeutics Inc. issued a press release and investor presentation regarding positive interim results from Part 1a of the Phase 2 study for its drug candidate DM199, intended to treat preeclampsia.
📋 Key Facts
- Announced positive interim results from Part 1a of the Phase 2 study of DM199.
- The clinical study focuses on the treatment of preeclampsia.
- Results were communicated via press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2).
- Filing date: July 17, 2025.
DiaMedica Therapeutics Inc. held its 2025 Annual General Meeting of Shareholders on May 15, 2025. The company reported the results of shareholder votes regarding director elections, auditor appointment, and executive compensation.
📋 Key Facts
- The 2025 AGM was held on May 15, 2025.
- A quorum was established with 19,344,190 Common Shares (45.1% of outstanding shares) represented in person or by proxy.
- All seven director nominees were elected to the Board: Michael Giuffre, Rick Kuntz, Tanya Lewis, Daniel O’Connor, James Parsons, Rick Pauls, and Charles Semba.
- Baker Tilly US, LLP was appointed as the independent registered public accounting firm for the year ending December 31, 2025.
- The advisory vote on executive compensation was approved.
DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and business updates.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 13, 2025
- The company provided condensed consolidated financial results via a press release (Exhibit 99.1).
- Filing includes business updates alongside the financial results.
DiaMedica Therapeutics Inc. announced its consolidated financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of full-year earnings and a business update.
📋 Key Facts
- Report date: March 17, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) providing a business update and full-year financial results.
- Company is listed on the Nasdaq Stock Market LLC under ticker DMAC.
DiaMedica Therapeutics Inc. announced the retirement of long-standing Director Richard Pilnik, who will not stand for re-election at the upcoming 2025 Annual General Meeting. The departure is characterized as a planned retirement due to succession planning and involves no disagreements with the company.
🚩 Red Flags
- Loss of long-term institutional knowledge (15+ years on board).
📋 Key Facts
- Richard Pilnik will retire from the Board of Directors following the 2025 AGM scheduled for May 15, 2025.
- Mr. Pilnik has served on the Board for over 15 years and was previously Chairman of the Board for over a decade.
- The departure is part of a broader succession planning effort; James Parsons recently took over as Chairman of the Board.
- Mr. Pilnik currently serves as Chair of the Nominating and Corporate Governance Committee and is a member of the Audit Committee.
- Daniel J. O’Connor was recently appointed to the Board as part of this transition.
DiaMedica Therapeutics Inc. announced the appointment of Daniel J. O’Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor will serve on both the Audit Committee and the Nominating and Corporate Governance Committee.
📋 Key Facts
- Daniel J. O’Connor appointed to the Board effective February 20, 2025.
- O'Connor will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
- Appointment includes an option to purchase 64,242 voting common shares vesting over three years in quarterly installments.
- The company entered into a standard indemnification agreement with Mr. O’Connor.
- O'Connor has extensive biotech leadership experience, including CEO roles at Ambrx Biopharma (acquired by J&J) and OncoSec Medical.
DiaMedica Therapeutics announced its Q3 2024 financial results and provided a business update regarding the ReMEDy2 Phase 2/3 clinical trial for DM199. The filing also includes an investor presentation detailing protocol and statistical analysis plan changes for said trial.
🚩 Red Flags
- Clinical trial protocol and statistical analysis plan changes can sometimes indicate attempts to salvage data or adjust endpoints, which may impact regulatory success probability.
📋 Key Facts
- Announced consolidated financial results for the three and nine-month periods ended September 30, 2024.
- Disclosed updates to the protocol and statistical analysis plan for the ReMEDy2 Phase 2/3 clinical trial (DM199) for acute ischemic stroke treatment.
- Issued an investor presentation regarding the ReMEDy2 trial updates.
DiaMedica Therapeutics Inc. announced its consolidated financial results for the three and six-month periods ended June 30, 2024. The filing serves as a formal announcement of the company's Q2 2024 business update and financial performance.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: August 7, 2024.
- The filing includes a press release (Exhibit 99.1) providing a business update and financial results.
DiaMedica Therapeutics Inc. entered into securities purchase agreements to conduct a private placement of 4,720,000 common shares at $2.50 per share. The company expects gross proceeds of approximately $11.8 million to fund clinical trials for preeclampsia and general working capital.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of 4.72 million new common shares.
- Registration Rights Agreement includes liquidated damages if filing deadlines are not met, creating operational pressure on the finance team.
- The need for a private placement often indicates a requirement for immediate liquidity to fund ongoing operations.
📋 Key Facts
- Private placement of 4,720,000 common shares at a price of $2.50 per share.
- Expected gross proceeds of $11.8 million (before fees/expenses).
- Closing is expected on or about June 28, 2024.
- The company will enter into a Registration Rights Agreement to register the shares for resale within 10 business days of closing.
- Use of proceeds: Expansion of clinical trials into preeclampsia and general working capital.
DiaMedica Therapeutics announced plans to expand its clinical trial program into preeclampsia, a life-threatening pregnancy-associated vascular disorder. The company provided an investor presentation to detail the strategic expansion of its DM199 product candidate.
🚩 Red Flags
- Forward-looking statements carry inherent risks regarding trial enrollment, costs, and regulatory approval timelines.
📋 Key Facts
- Company plans to expand clinical trials for DM199 into the treatment of preeclampsia.
- The expansion involves a planned Phase 2 trial for preeclampsia.
- An investor presentation was released on June 26, 2024, to support the announcement (Exhibit 99.1).
- The company issued a press release regarding the clinical expansion (Exhibit 99.2).
DiaMedica Therapeutics Inc. held its 2024 Annual General Meeting of Shareholders on May 22, 2024. The meeting resulted in the election of seven directors and approval of several key proposals, including an amendment to increase shares available under the company's Omnibus Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual General Meeting held on May 22, 2024.
- Shareholders approved an amendment to the 2019 Omnibus Incentive Plan to increase share availability by 3,000,000 shares.
- All seven director nominees were elected to serve until the next AGM or their successors.
- Baker Tilly US, LLP was appointed as the independent registered public accounting firm for the year ending Dec 31, 2024.
- Shareholders approved executive compensation on an advisory basis and opted for a 1-year frequency for future 'say-on-pay' votes.
DiaMedica Therapeutics Inc. announced its consolidated financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the company's quarterly business update and financial performance.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024
- Filing date: May 8, 2024
- The filing includes a press release (Exhibit 99.1) providing a business update and Q1 2024 financial results.
DiaMedica Therapeutics announced the resignation of Julie VanOrsdel Daves, Senior Vice President of Clinical Development Operations, effective April 18, 2024. Rebekah de Vitry Fries will assume leadership of clinical operations to ensure a smooth transition.
🚩 Red Flags
- Departure of a high-level executive (SVP) in a critical functional area (Clinical Development Operations).
📋 Key Facts
- Julie VanOrsdel Daves resigned as SVP, Clinical Development Operations on April 5, 2024.
- Resignation is effective as of April 18, 2024.
- The departure is for personal reasons.
- Rebekah de Vitry Fries (VP of Clinical Operations) will assume leadership of clinical operations.
- Ms. De Vitry Fries joined the company full-time on February 20, 2024.
DiaMedica Therapeutics Inc. announced its consolidated financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual business update and financial performance.
📋 Key Facts
- Reporting period: Full year ended December 31, 2023.
- Filing date: March 19, 2024.
- The filing includes a press release (Exhibit 99.1) containing business updates and financial results.